Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
04:05am, Tuesday, 23'rd Sep 2025
The healthcare sector is both large and important, and one of its most exciting areas is the pharmaceutical niche. That's always true from a development standpoint.
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
10:21am, Monday, 22'nd Sep 2025
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
04:44am, Sunday, 21'st Sep 2025
You may notice a few common denominators with most of the 10 companies with market caps of at least $1 trillion. All but one of them focus on technology.
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
04:46am, Saturday, 20'th Sep 2025
It is tempting for a dividend investor to simply select the highest yielding stocks. The problem with that approach is that it exposes you to the risk of dividend cuts if the yield is too high for the
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of
I Hit My First $1,000 in Annual Dividends – Here’s How I Did It
10:00am, Friday, 19'th Sep 2025
Dividends have gained immense popularity lately. It could be due to the interest rate cuts this month, sending investors back to equities looking for a higher yield, or it could be due to the growing
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study TORONTO , Sept. 19, 2025 /PRNewswi
Pending the European Commission's final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibo
Top Wide-Moat Stocks Worth a Look for Sustainable Growth
08:11am, Friday, 19'th Sep 2025
MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.
8 Dividend Growth Stocks Every Investor Should Consider
05:45am, Friday, 19'th Sep 2025
Forget the dividend darlings everyone already owns -- the real money in income investing comes from companies raising their payouts faster than inflation while keeping enough cash to reinvest in growt
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
06:46pm, Thursday, 18'th Sep 2025
Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
03:46pm, Thursday, 18'th Sep 2025
Nanobiotix SA NBTX announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
12:31pm, Thursday, 18'th Sep 2025
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase
J&J's experimental psoriasis drug shows promise against Bristol's treatment
08:27am, Wednesday, 17'th Sep 2025
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
